24/7 Wall Street
16 Feb 2026, 19:00 UTC · 36w ago
Verdict
Headline takes no side. We score LLY +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Eli Lilly reported Q4 EPS of $7.54 (beating the $6.67 estimate) and projected 2026 revenue of $80-83 billion.
So whatStrong earnings beats combined with high forward guidance typically trigger immediate positive price action and valuation upgrades.
More positive than 99% of claims this week
Eli Lilly's GLP-1 drug revenues surged in Q4, with Mounjaro growing 110% to $7.4B and Zepbound growing 123% to $4.2B.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 98% of claims this week
Novo Nordisk projects sales growth of -5% to -13% for 2026 due to pricing pressures.
So whatNegative growth guidance for a primary competitor signals sector headwinds and a potential shift in market share toward Eli Lilly.
More negative than 95% of claims this week
Eli Lilly has stockpiled $1.5 billion of its oral GLP-1 candidate, orforglipron, ahead of an April 2026 FDA decision.
More positive than 85% of claims this week
Eli Lilly and Nvidia established a co-innovation lab to integrate clinical data with computational capabilities for AI-driven R&D.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Reported a significant Q4 earnings beat, strong GLP-1 revenue growth, and positive 2026 revenue projections.
More negative than 92% of ticker scores this week
Projecting negative sales growth for 2026 amid pricing pressures and losing market share to Eli Lilly.
More positive than 68% of ticker scores this week
Mentioned as having delivered strong third-quarter results.
More positive than 59% of ticker scores this week
Mentioned as a partner in a $1 billion AI co-innovation lab with Eli Lilly to interrogate biology at scale.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
5h ago
More positive than 74% of relationship scores this week
[mutual] Eli Lilly and Nvidia established a co-innovation lab to link clinical data with computational capabilities.
+36.3%
Price agrees with the score
$1417.54 vs $1040.00 close before publication (Feb 13) · not market-adjusted
LLY chart →
